Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical Business ReviewJascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Business Review Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPFNext: Regeneron immunotherapy combo comes up short in melanoma trial Related Stories Regulatory Novo Nordisk comeback stirs as Wegovy pill wins UK approval pharminent June 12, 2026 Regulatory Lilly wins new FDA approval for eczema drug Ebglyss pharminent June 10, 2026 Regulatory Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug pharminent June 10, 2026
